Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 12 (8), 909-17

Simeprevir for the Treatment of Chronic Hepatitis C Genotype 1 Infection

Affiliations
Review

Simeprevir for the Treatment of Chronic Hepatitis C Genotype 1 Infection

Tetsuo Takehara. Expert Rev Anti Infect Ther.

Abstract

Simeprevir is a second-wave hepatitis C virus NS3/4A protease inhibitor that was designed to optimize its antiviral activity, safety, drug-drug interactions, and pharmacokinetic profile. When used to treat patients with hepatitis C virus genotype 1, simeprevir is coadministered with peginterferon and ribavirin for 12 weeks, followed by double therapy with Peg-IFN and ribavirin for an additional 12 or 36 weeks. Phase III studies achieved a sustained virologic response in 80-90% of treatment-naïve patients (International Phase III studies QUEST-1/2: 80/81%; Japanese Phase III trial CONCERTO-1: 89%). Unlike with the first protease inhibitors, telaprevir or boceprevir, used in triple therapy, when using simeprevir the frequency of clinically problematic adverse events such as anemia, rash, and digestive symptoms is almost comparable to that of double therapy. The advent of simeprevir has enabled interferon therapy, which started as monotherapy in early 1990s, to reach its maximum efficacy and arrive at what can be considered its final form at least in genotype 1b.

Keywords: Simeprevir; direct acting antiviral; hepatitis C virus; peginterferon; protease inhibitor.

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

MeSH terms

Feedback